Skip to content

Metabolic

Amycretin

InjectableEvidence BOnce a week
Half-life
120hours
Typical vial
10 / 20mg
Research amounts
5–20mg

per administration

Common schedule
Once a week
Some human use

It has been used in people, but no trial has settled how much or how often.

Work out your draw

These numbers are a starting point — change any of them.

3 mL cartridge · 300 units loaded150units dialled
Concentration
3.33mg/mL
Volume per draw
1.5mL
Units to dial
150
Doses per cartridge
2

This is 150 units, past the 60-unit dial. Splitting it across administrations, or using less water to raise the concentration, brings it back into range.

Dial range varies by pen; 1–60 units is the common configuration.

Vial label

Copy this into your label printer.

Published research contexts for Amycretin describe 520 mg per administration. Descriptive only, not a recommendation.

Multi-day for the subcutaneous form; human figures are early-phase and not well characterized.

A unimolecular amylin and GLP-1 receptor co-agonist studied for weight reduction in phase 1/2 research. No confirmed dose-ranging publication fixes a subcutaneous schedule, so no schedule table is shown.

Modelled level — once a week

1× is the peak after a single dose.

Steady-state peak
1.57× single dose

Read off the modelled curve, not an even-interval formula

Time to steady state
25.0days

About five half-lives

Administrations
1/ week

Where these numbers come from

  • Amycretin early-phase program (Novo Nordisk)Amylin/GLP-1 co-agonist in early-phase weight research; subcutaneous amounts are not schedule-establishing.

Next steps